Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia

 Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia

Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia

 Shots:

  • The approval is based on non-inferiority data with the reference biologic (Neulasta) showing biosimilarity in terms of safety, efficacy and quality
  • Ziextenzo is a long-lasting form of filgrastim indicated to reduce duration of neutropenia and occurrence of febrile neutropenia in adult treated with cytotoxic (anti-cancer) CT
  • Sandoz has received eight biosimilars approval worldwide, with five in the last 18 months

Click here to read full press release/ article | Ref: Sandoz | Image: Datacenter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post